[Myocardial imaging using PET and SPECT].

N Tamaki; K Morita

Home/Archive/PubMed

PubMed · 9796318

[Myocardial imaging using PET and SPECT].

N Tamaki·K Morita

View original source ↗Export metadata ↓

Abstract

Positron emission tomography (PET) has been used for quantitative analysis of regional myocardial blood flow and metabolism in vivo in these patients. Ischemic myocardium can be identified as an area of enhanced F-18 fluorodeoxyglucose (FDG) uptake as a marker exogenous glucose utilization. Because of limited availability of PET studies, a number of modified methods have been introduced for metabolic imaging in vivo. I-123 betamethyl iodophenyl pentadecanoic acid (BMIPP) has been used to probe free fatty acid metabolism using SPECT cameras. Ischemic myocardium has been identified as an area of reduced BMIPP uptake, probably due to altered metabolism in repetitive ischemic episodes. Such reduction of BMIPP uptake is more likely seen in patients with unstable angina or vasospastic angina where regional wall motion abnormalities are associated. In addition, severely ischemic myocardium has been identified as an areas of reduced uptake of I-123 metaiodobenzyl guanidine (MIBG) as a marker of adrenergic neuronal function. These biochemical imaging should be valuable for identifying severely ischemic myocardium and assessing severity of ischemic insult.

Explore related subjects

3-Iodobenzylguanidine Acute Disease Coronary Circulation Coronary Disease Energy Metabolism Fatty Acids Heart Humans Iodine Radioisotopes Iodobenzenes Myocardium Radiopharmaceuticals Syndrome Tomography, Emission-Computed Tomography, Emission-Computed, Single-Photon Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

N Tamaki, K Morita. 1998. [Myocardial imaging using PET and SPECT].. https://pubmed.ncbi.nlm.nih.gov/9796318/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Targeting neuronal dysfunction and receptor imaging.

The sympathetic nervous system has great influence on cardiovascular physiology, and the importance of cardiac innervation abnormalities in the physiopathology of various cardiac diseases has been emphasized. Cardiac neurotransmission imaging with single-photon emission computed tomography (SPECT) allows in vivo assessment of the myocardial nervous system. At present, the most commonly used SPECT tracer to assess cardiac neurotransmission is metaiodobenzylguanidine labelled with iodine-123 ((123)I-MIBG). In patients with heart transplantation, ischemic heart disease, dysautonomias and drug-induced cardiotoxicity, assessment of neuronal function can help characterise the disease and improve the prognostic stratification. Cardiac (123)I-MIBG scintigraphy allows autonomic neuropathy to be detected in the early stages of diabetes mellitus. In patients with heart failure, the assessment of cardiac sympathetic activity has important prognostic implications. Future directions in cardiac sympathetic neurotransmission include the development of new tracers, targeting of second-messenger molecules and early assessment of cardiac neurotransmission in genetically predisposed subjects for prevention of heart failure.

3-Iodobenzylguanidine↗

PubMed2007

Molecular imaging in heart failure.

Heart failure (HF), a heterogeneous syndrome of epidemic proportions, is increasingly defined by its underlying molecular and genomic alterations. Molecular cardiac imaging has emerged as a complementary discipline that has improved the understanding of the pathophysiologic principles governing experimental HF and has a potential to revolutionize assessment and management of HF in humans.

3-Iodobenzylguanidine↗

PubMed2007

Decline of neuroadrenergic bronchial innervation and respiratory function in type 1 diabetes mellitus: a longitudinal study.

BACKGROUND AND AIM: Type 1 diabetes mellitus complicated by autonomic neuropathy (AN) is characterized by depressed cholinergic bronchomotor tone and neuroadrenergic denervation of the lung. We explored the effects of AN on the rate of decline of pulmonary sympathetic innervation and respiratory function during a 5-year follow-up. METHODS: Twenty diabetic patients, 11 with AN, were enrolled in 1998 and then followed-up until 2003. During follow-up, glycosylated haemoglobin (HbA1c) was measured every 3 months. In 1998 and 2003 the patients underwent respiratory function tests and a ventilatory scintigraphic study of neuroadrenergic bronchial innervation using 123I-MIBG. RESULTS: During follow-up 4 patients, all with AN, were lost, and 1 developed AN. Forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) showed comparable rates of decrease in patients with and without AN. The yearly decline of forced expiratory volume in 1 s (FEV1) was about double the physiologic rate, in both AN and AN-free patients. The MIBG clearance significantly increased both in patients with AN (T1/2: 118.88 +/- 30.14 min at baseline and 92.10 +/- 24.52 min at the end of follow-up) and without AN (135.14 +/- 17.09 min and 92.68 +/- 13.52 min, respectively), indicating a rapidly progressive neuroadrenergic denervation. The rate of the neuroadrenergic denervation was inversely related to the severity of autonomic dysfunction at baseline (Spearman's rho - 0.62, p = 0.017). Neither respiratory function indexes nor MIBG clearance changes correlated with the overall HbA1c values. CONCLUSIONS: Neuroadrenergic denervation of the lung parallels the decline of respiratory function indexes in diabetic patients both with and without AN and seems to be independent from the quality of glycemic control.

3-Iodobenzylguanidine↗